Melissa Dubois, NP
Nurse Practitioner · Woodstock, GANPI 1871988360
Payments from drug & device makers
Across 373 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Pfizer$699
- AstraZeneca$664
- Lilly USA, LLC$608
- Takeda Pharmaceuticals U.S.A., Inc.$406
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $1,144 |
| AbbVie | 53 | $1,020 |
| Pfizer | 35 | $699 |
| AstraZeneca | 34 | $664 |
| Lilly USA, LLC | 39 | $608 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $406 |
| Amarin Pharma, Inc. | 24 | $405 |
| Astellas Pharma US Inc | 9 | $212 |
| Organogenesis Inc. | 7 | $205 |
| Amgen(2 entities) | 11 | $173 |
| Merz North America, Inc. | 2 | $172 |
| Boehringer Ingelheim | 9 | $154 |
| Exact Sciences | 9 | $142 |
| Biohaven Pharmaceuticals, Inc. | 7 | $132 |
| GSK | 7 | $132 |
| Merck | 7 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $87 |
| Abbott | 4 | $63 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Antares Pharma, Inc. | 2 | $42 |
| Nevro Corp. | 2 | $39 |
| Bausch Health US, LLC | 2 | $35 |
| Pulmonx Corporation | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Medtronic | 1 | $30 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,112 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 35 | $36,342 |
| OzempicSemaglutide | 14 | $13,789 |
| Repatha SyringeEvolocumab | 13 | $8,228 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,506 |
| SynthroidLevothyroxine Sodium | 27 | $2,756 |
| Atorvastatin Calcium | 75 | $1,009 |
| Levothyroxine Sodium | 138 | $942 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $871 |
| Rosuvastatin Calcium | 96 | $804 |
| Omeprazole | 36 | $801 |
| Losartan Potassium | 100 | $732 |
| Azelastine Hcl | 34 | $703 |
| Metoprolol Succinate | 61 | $630 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 29 | $623 |
| Pantoprazole Sodium | 43 | $582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $608 | $36,34235 claims |
| Novo NordiskOzempic | $1,144 | $13,78914 claims |
| AbbVieSynthroid | $1,020 | $2,75627 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $942138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Woodstock
- Mary BedingfieldWoodstock$16K
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
- Afsha HussainiKennesaw$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.